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We report the functional and structural analysis of the 5’ untranslated region (S’UTR) of human hepatoma HepG2 y-glutamyltransferase (GGT) 
mRNA. Transient expression of a hybrid GGT-luciferase gene in HepG2, MIA-Pa-Ca-2 and MG 63 cell lines shows that this YUTR acts as a 
tissue-specific translational enhancer. Evidence for transcripts with multiple 5’UTR coding for HepG2 GGT was obtained by RNase protection. 
Computer analysis of this S’UTR detected the existence of a stable stem and loop structure containing multiple steroid modulatory elements. 
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1. INTRODUCTION 
y-Glutamyltransferase ((5-glutamyl)-peptide: amino 
acid 5 glutamyl-transferase, EC 2.3.2.2) is a glycosyl- 
ated, plasma membrane heterodimeric enzyme involved 
in the metabolism of glutathione and its derivatives [l]. 
GGT is expressed in various mammalian tissues. GGT 
mRNA level is elevated in fetal liver and is decreased 
in adult liver whereas in kidney tissue GGT expression 
increases during development [2]. Increase of GGT ac- 
tivity is also observed in hepatocarcinoma [3], whereas 
decreased activity is observed in kidney cancer or pan- 
creatic neoplasia [4]. GGT activity increases after drug 
and ethanol administration [5] and also after induction 
by steroid hormones [6]. 
on the translatability of GGT mRNA has been pre- 
sented. This report describes for the tist time the inllu- 
ence of the HepG2 S’UTR on the translation of a luci- 
ferase reporter gene construct transfected into three dif- 
ferent human cell lines and the structural features of this 
S’UTR involved in translation efficiency. 
2. MATERIALS AND METHODS 
2.1. Ceils and medium 
HepG2 (human hepatocyte carcinoma), MG-63 (human osteosar- 
coma) and MIA-Pa-Ca-2 (human pancreatic carcinoma) were cul- 
tured in Dulbecco’s mod&d Eagle’s medium (Gibco-BRL) contain- 
ing 10% (v/v) fetal calf serum (Boehringer, Mannheim) and 5% (v/v) 
antibiotic;antimitotic (Gibco-BRL). All cell lines were obtained from 
ECCAC. 
GGT mRNAs have been identified in different 
human tissues: placenta [7], HepG2 hepatoma [8], kid- 
ney 191, pancreas [lo], adult and fetal liver [ll]. The 
coding regions of the corresponding cDNAs are 100% 
homologous; minor forms of human and fetal liver 
cDNAs present an insertion of 22 bp. The S’UTR of all 
these mRNAs are unusually long (over 300 b) and pres- 
ent a set of highly heterogeneous regions [lo]. 
2.2. Construction of expression vectors 
phGGT [S] with the HepG2 hepatoma GGT cDNA was sequen- 
tially digested by EcoRI and SmuI, then with NfaIII @I.E. Biolabs). 
The final EcoRI-NlalII fragment containing 489 bp of 5’UTR and 
89 bp of the GGT protein-coding region was subcloned in a pGEM- 
32 vector @omega). This construct (p5’GGT) was used for in vitro 
transcription. 
In eukaryotic cells, translation is believed to take 
place by a scanning model [ 121. Different structural fea- 
tures on 5’ and 3’UTR, including upstream open read- 
ing frames, loops, bulges and pseudoknots, have been 
shown to influence this mechanism. Until now no study 
In order to make reporter gene constructs, the S’UTR was arnpliied 
by PCR from p5’GGT and subcloned into pSV2Luc [13] linearized by 
Hind111 (N.E. Biolabs). The final constructs were called pSVS’-3’GGT 
and pSV3’-S’GGT following the orientation of the S’UTR insert. Rel- 
evant regions of the fmal constructs were conlirmed by sequencing in 
both directions using a T7 sequencing kit (Pharmacia). Other recom- 
binant techniques were carried out according to the literature [14]. 
2.3. Transfection protocol 
*Corresponding author. Fax: (33) 83 32 13 22. 
Abbreviations: b, base(s); bp, base pairs; GGT, y-glutamyltransferase; 
nt, nucleotide(s); Tricine, N-[2-hydroxymethyl)ethyl]-glycine; S’UTR, 
5’ untranslated region. 
Electroporation was realized following [15] with modifications. 
Cells were harvested at 75% confluency after trypsin/EDTA (Gibco- 
BRL) treatment and resuspended in fresh serum-free medium. 
0.5 x lo6 cells of each cell line were used at a concentration of 1.5 x lo7 
cells/ml for each electroporation with the following settings: 725 V/cm 
and 960 PF for HepG2 and MIA-Pa-Ca-2; 700 V/cm and 960 PF for 
88 Published by Elsevier Science Publishers B. K 
Volume 332, number 1,2 FEBS LETTERS October 1993 
MG-63 (Biorad Gene Pulser). 20 pg of each reporter gene construct 
were used. Transfections were normalied by co-transfection of 15 /Ig 
pCMVp plasmid (Clontech) expressing /I-galactosidase. pGEM-3Z 
plasmid was used as a negative control. After transfection, cells were 
cultured in 10 ml pre-heated complete medium. 
2.4. Reporter gene assays 
Reporter gene analysis was realized as described by [13] with the 
following modifications. 48 h after transfection the cells were washed 
with phosphate-buffered saline (137 mM NaCl, 2.7 mM KCl, 4.3 mM 
Na,HPG.,, 1.4 mM KH,PO,,, pH 7.3) and were lysed in Reporter lysis 
buffer (Promega). A supematant was prepared after a centrifugation 
of the lysed cells at 14,000 x g for 5 min at 4°C and used for further 
study. 
Light emission resulting from h&erase activity was measured in a 
Lumac-3M luminometer by integration of peak light emission over 
10 s at 2YC. Luciferase assay buffer @omega) contained 20 mM 
Tricine, 1.07 mM (MgCO,),Mg(OH),, 2.67 mM MgSO,, 0.01 mM 
EDTA, 33.3 mM dithiothreitol, 0.27 mM coenxyme A, 0.47 mM 
luciferin, 0.53 mM ATP and 2-10 ~1 of the supematant. 
/I-Galactosidase activities were measured in an assay buffer contain- 
ing 100 mM sodium phosphate @H 7.3), 1 mM MgCl,, 50 mM /I- 
mercaptoethanol, 0.665 mg/ml o-nitrophenyl-/3-n-galactopyranoside 
and 2-10 ~1 of supematant. After incubation at 37°C for 30 min the 
reaction was stopped with 1 M sodium carbonate and optical densities 
were measured at 405 nm. 
The ratio between arbitrary luciferase light units and /I-galactosi- 
dase activity was expressed per ~1 of supematant and was normalized 
for each cell hue separately relative to the cells transfected with 
pSV2Luc detined as 100%. Each value is the average of the results of 
at least three independent transfection experiments. Assays were re- 
peated twice. 
2.5. RNA analysis 
Ribonuclease protection were performed according to Melton and 
Krieg [16] with 20 pg of HepG2 total RNA isolated as described by 
Chirgwin et al. [17]. The 600 b antisense probe carries the 489 b SUTR 
and 89 b coding region of phGGT. This probe was synthetixed by SP6 
RNA polymerase (Promega) after linearization of 5’GGT by EcoRI 
@I.E. Biolabs). 
2.6. Sequence analysis 
Secondary structure predictions were generated on a Digital Equip- 
ment Corporation MicroVax computer using the FOLD program [18]. 
FINDPATTERNS was used to search for steroid modulatory ele- 
ments. FRAMES was used to search for open reading frames. All 
programs are included in the Genetics Computer Group package of 
the University of Wisconsin. 
3. RESULTS 
The translational efficiency of most eukaryotic 
mRNAs is under the control of structural elements uch 
as modulatory response elements, upstream open read- 
ing frames and regions with a high degree of secondary 
structure. cDNAs coding for human GGT have been 
shown to present multiple S’UTR expressed in a tissue- 
specific manner. All of these S’UTR have an unusually 
large size: 669 b for placenta [7j, 489 b for HepG2 [8], 
715 b for fetal liver [9], 358 b for pancreas [lo]. No 
studies dealing with the influence of these regions in 
translational efficiency or stability of GGT mRNA have 
been presented so far. We have used the HepG2 GGT 
SUTR as a model to investigate the role of this se- 
quence in the translation of a hybrid GGT-luciferase 
NldWSphI 
HindIII HidIII 
psv34+Luc 
HindIII HindlII 
Fig. 1. Schematic representation ofplasmid used for in vitro transcrip- 
tion (PS’GGT) and plasmids harbouring the HepG2 GGT S’UTR in 
both orientations @SVS-3’Luc and pSVY-5’Luc). SP6 and T7 repre- 
sent RNA polymerase promoters. 
reporter gene construct in three cell lines of different 
tissue origin. 
For this analysis, we subcloned the SUTR of the 
human hepatoma HepG2 GGT cDNA upstream from 
the luciferase-encoding ene driven by an SV40 pro- 
moter (Fig. 1). Both native and reverse orientations 
were obtained relative to the promoter and the final 
constructs were termed pSVS’-3’Luc and pSV3’-5’Luc. 
Both constructs were introduced by electroporation 
into three different human cell lines known to have 
different levels of GGT expression. The plasmid 
pCMVpga1 expressing /3-galactosidase under the con- 
trol of the CMV promoter was used to normalize trans- 
fection efficiency. 48 h after transfection cells were har- 
vested and extracts were prepared to measure reporter 
gene activity. 
Normalized luciferase activities are represented in 
Table I 
Comparison of the degree of stimulation of luciferase activities by 
HepG2 GGT S’UTR in three different cell lines transfected with re- 
porter gene constructs 
Cell line Construct Luciferase activity 
(light units&l) 
HepG2 
Ma-Pia-Ca-2 
MG-63 
pSV2Luc 
pSVS’-3’Luc 
psv3’-52uc 
pSV2Luc 
psvs-3’Luc 
psv3’-S’LUC 
pSV2Luc 
psvs-3’Luc 
psv3’-SLUC 
579.80 + 103.30 
909.30 + 130.15 
10.00 + 1.20 
73.26 + 6.40 
224.90 f 6.30 
2.00 f 0.20 
38.70 f 0.90 
200.10 f 55.30 
5.70 + 0.26 
Luciferase activity is expressed as the ratio of arbitrary light units/ 
units of &galactosidase&l of sample x 103. Results are expressed as 
a mean & S.E.M. of at least three independent experiments. Assays 
were done in duplicate. 
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HepG2 
pSV2Luc 
psw3’Luc 
psvs-B’LUC 
psV2Luc 
MIA-Pa-&2 pSVs’S’Luc 
psw-b’Luc 
MG63 
pSV2Luc 
pSVG-S’LUC 
Lsv3’-S’LUC 
f I I I 
0 100 300 500 700 
Luciferase activity (%) 
Fig. 2. The effect of HepG2 GGT S’UTR on luciferase activity in three 
human cell lines. For each cell line, results are expressed as a percent- 
age of normalized luciferase activity with 100% for pSV2Luc. Each bar 
represents the mean + S.E.M. of at least three independent experi- 
ments. Assays were repeated twice. See text for other details. 
Table I and Fig. 2 The results show clearly that the 
presence of the S’UTR enhances luciferase expression 
in all three cell lines in cis, as compared to cells trans- 
fected with the control plasmid. When the results are 
expressed as a percentage of the basal pSV2Luc activity 
of each transfected cell line, HepG2 cells show an 1.6- 
fold increase in luciferase activity. A higher increase is 
observed for MIA-Pa-Ca-2 (4.1-fold) and MG-63 cells 
(5.2-fold). pGEM-3Z plasmid-transfected cells did not 
show any luciferase activity and neither did untrans- 
fected cells in the presence of pSV2Luc. All three cell 
lines transfected with plasmid pSV3’-5’Luc that carries 
the S’UTR in the non-physiological orientation show a 
very low reporter gene activity (HepG2, 10.0%; Mia-Pa- 
Ca- 2, 2.0%, and MG63, 5.7%) (Table I and Fig. 2). 
The FOLD program was used to ascertain the pres- 
ence of possible secondary structures in the studied 
SUTR (Fig. 3). The analysis showed that there are 
multiple inverted repeats potentially able to form one 
stem-and-loop secondary structure with a free energy of 
formation of G = -3 1.8 kcal/mol localized between 
nt = 262 and nt = 366. FINDPATTERNS located three 
glucocorticoid modulatory elements (AGAAGA) at 
nt = 309, nt = 315 and nt = 340. These elements are 
known to be involved in post-transcriptional regulation 
by stimulation of translation [19] in response to steroid 
hormone treatment. FRAMES located an upstream 
open reading frame in the inverted S’UTR of pSV3’- 
SLUC. 
To determine the size of the GGT transcripts ex- 
pressed in HepG2 cells we used RNase protection as- 
says. The probe was antisense RNA synthethized in 
vitro from p5’GGT (Fig. 1). This probe contains 489 b 
corresponding to the HepG2 hepatoma S’UTR and 
89 b complementary to the GGT coding region of 
GGT. The part of the coding region is 100% identical 
in the cDNAs of all the GGT transcripts cloned so far 
from human tissues. Any heterogeneity in the length of 
the protected fragment should therefore be due to dif- 
ferences in the S’UTR of mRNA expressed by HepG2 
90 
260 270 280 260 300 
--AR - 
310 
-C --G UA c cc ccuu 
RGGUCUO GGCUGCG GU 
- AACG 
CUUCAGG AC UC UUGR 
UUCGGAC UCGGUGU UR 
CFlGO AG A 
GAAGUCC UG f10 GACU 
CGAC 
GUCC UC G 
A CU GACl -C - -R ___A 
360 
0 GGAA 
350 340 330 320 
Fig. 3. Secondary structure analysis of the SUTR. This hairpin struc- 
ture has been obtained by using the FOLD program of the GCG UW 
software package on a Digital Equipment Corporation computer. 
Estimated free energy is G = -31.8 kcal/mol. Steroid hormone modu- 
latory elements are represented in bold. 
hepatoma. Based on the published sequence, hybridiza- 
tion of the antisense probe should produce a protected 
band of 578 b. Our results reveal the existence of four 
protected fragments of differents of different lengths 
after RNase A/T1 digestion (Fig. 4): 580, 500, 480 and 
350 bases. No protected fragments were observed when 
yeast tRNA was used as a negative control. Digestion 
times of 15, 30,45 and 60 min did not alter the number 
and intensity of the protected fragments, thus confirm- 
ing the specificity of the detected bands. The intensity 
of the protected fragments differed between fragments, 
but the relative intensities of the bands were constant 
regardless of the length of RNase digestion. These re- 
sults suggest he existence of multiple GGT transcripts 
expressed in HepG2 cells. These transcripts are present 
in various quantities and differ by their 5’UTRs. 
4. DISCUSSION 
S’UTR regulatory sequence elements of eukaryotic 
mRNA are less well studied than the 3’UTR elements. 
A few elements, like the steroid modulatory element 
[19], the HIV TAR sequence [20], the iron response 
element [21], and human FGF c&acting elements [22], 
have been described as implicated in translational regu- 
lation. 
We consider GGT to be a part of the housekeeping 
gene families expressed in almost all human tissues [lo]. 
These type of genes are known to be regulated at post- 
transcriptional evels rather than at the level of tran- 
scription [23]. Transcriptionally Kurauchi et al. [24] 
have shown that the genomic sequences coding for rat 
GGT lack typical promoter signals, leading to the con- 
clusion that at least the rat GGT gene is transcribed at 
a constitutive and weakly regulatable level. Neverthe- 
less housekeeping ene expression has to be modulated 
in order to respond to various environmental changes. 
The 5’ and also 3’UTR are known to be good candidates 
for carrying c&acting modulatory sequences respond- 
ing to truns-acting factors. S’UTR have been shown to 
interact with multiple regulatory proteins including 
Xenopus mRNA binding proteins p56 and p54 [25] and 
ferritin mRNA binding protein p90 [26]. These elements 
have been shown to be acting in experimental in vitro 
transfection systems, thus validating our approach. 
To investigate the influence of the GGT S’UTR on 
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Fig. 4. Ribonw&xse protection assays. Undigested probe (1); digested probe (2); yeast tRNA (20 hg) (3); HepG2 total RNA (20 pug) (4-7) after 
15, 30, 45 and 60 min of digestion, respectively. 5x lo6 cpm of @-“PfCIP (800 Ciimmol) labeled probe was used for each sample. 
translation efficiency in different tissues, we transfected 
three different human cell lines with SUTR-GGT-lucif- 
erase constructs. We found an 1.6-fold increase of re- 
porter gen activity in HepG2 hepatoma, 4.1-fold in- 
crease for Mia-Pa-Ca-2 and 5.2-fold increase for MG- 
63. Luciferase expression by the control plasmid, 
pSV2Luc, is 8-times lower in transfected Mia-Pa-Ca-2 
cells and 1 S-times lower in transfected MG63 compared 
to transfected HepG2 hepatoma. This ~~e~ntial ex- 
pression is most probably due to differences in pro- 
moter efficiency in the different cell lines. At the same 
time the pSVS-3’Luc transfected Mia-Pa-Ca-2 and 
MG63 cells show a 4.5times less luciferase activity 
compared to HepG2. Thus, we can conclude that the 
increase of luciferase activity is presumably due to the 
S’UTR of HepG2 and not to be differences in promoter 
expression efficiency in the different cells. 
The increase of luciferase expression by the presence 
of the HepG2 GGT S’UTR could be explained by an 
increased translation initiation efficiency. Moreover, 
these c&-acting elements, stem-and-loop structures or 
other possible elements not yet characterized for this 
system, seem to act in a tissue-specific manner since they 
appear to be recognized with different efficiencies by 
truns-acting factors synthesized by the three cell lines. 
These factors are likely to be tissue-specific transla- 
tional regulators. 
Regions of secondary structure in the RNA have been 
shown to influence the efficiency of translation initia- 
tion, possibly by interacting with these translational 
trans-acting factors. In a search for potential secondary 
structure regions on the hepatoma S’UTR, we found a 
stable structure between nt = 262 and nt = 366 present- 
ing a free energy of formation of -31.8 kcal/mol. The 
role of such secondary structures is being investigated 
by other groups. The structure of the S’UTR has al- 
ready been shown to influence efficiency of translation 
initiation. Pelletier and Sonenberg [27] were able to de- 
crease thymidine kinase mRNA translation efficiency 
by introducing oligonucleotide sequences which 
changed the secondary structure of the 5’UTR. In con- 
trast Hentze et al. [28] were able to show the existence 
of vital secondary structures in the S’UTR of ferritin 
mRNA able to interact with regulatory protein p90. 
Stable secondary structures in SUTR are necessary for 
efficient expression of glutathione peroxidase [29] or 
ornithine decarboxylase PO]. It is possible that these 
structures are responsible for the binding of protein 
factors able to modify translation by enhancing or slow- 
ing down the translational machinery. With regard to 
this, it is worth noting that interaction of components 
of the translational machinery like eIF-4A, with second- 
ary structures seem to play a determining role [31]. 
RNase protection analyses howed that four different 
transcripts are expressed in human hepatoma HepG2 
cells. These transcripts present sequence heterogeneity 
with a common part in the SUTR. This is the first time 
that multiple GGT messages have been shown to be 
expressed in the same cells. This type of heterogeneity 
within the 5’UTR has already been shown for rat GGT 
transcripts. Chobert et al. 1321 obtained two different 
transepts coding for rat kidney GGT differing only by 
20 b at the 5’ end of the SUTR. A third cDNA isolated 
by Manson et al. [33] coding for rat liver GGT differs 
by 58 b from the rat GGT cDNAs. Human GGT cDNA 
are also known to present multiple S’UTR expressed in 
different tissues. This type of heterogeneity has also 
been demonstrated for multiple human proteins, like 
the myosine light chain [34]. Heterogeneity in the 
5’UTR appears to be part of a complex mode of post- 
transcriptional regulation of GGT expression: alterna- 
tive 5’UTRs allow the expression of GGT under differ- 
ent cytoplasmic conditions. These conditions may vary 
during ontogenesis as well as during c~cinogenesis or 
induction by drugs or xenobiotics. 
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